Zogenix (NASDAQ: ZGNX) announced that dosing has begun in patients enrolled in its Relday multi-dose Phase 1b clinical study. Relday ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE